Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
Zepbound (tirzepatide) is a GIP/GLP-1 receptor agonist approved for chronic weight management, and it may affect thyroid levels in certain individuals, primarily through potential stimulation of thyroid C-cells. While clinical data in humans shows no consistent changes in TSH, T3, or T4, the FDA label includes a black box warning about thyroid C-cell tumors observed in animal studies. Understanding this interaction is crucial for patients considering Zepbound Today, especially those with a personal or family history of medullary thyroid carcinoma (MTC).
Zepbound mimics the actions of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which regulate appetite and insulin secretion. These hormones also bind to receptors in the thyroid gland, particularly on C-cells that produce calcitonin. In rodent studies, prolonged activation led to C-cell hyperplasia and tumors. However, human studies have not demonstrated a similar risk at therapeutic doses, but the uncertainty remains.
| Population | Risk Level | Recommendation |
|---|---|---|
| General patients | Low | Baseline thyroid panel (TSH, free T4, calcitonin) recommended |
| Family history of MTC | High | Zepbound contraindicated; genetic testing for RET mutation |
| Personal history of thyroid nodules | Moderate | Ultrasound and calcitonin monitoring |
Phase 3 trials for Zepbound (SURMOUNT-1 through -4) monitored thyroid function tests. Pooled data showed no significant mean changes in TSH, T3, or T4 after 72 weeks of therapy compared to placebo. A small subset of participants (less than 1%) experienced transient increases in calcitonin above normal, but these did not correlate with nodules or malignancies. Long-term surveillance data through continues to support a favorable safety profile, though the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for MTC.
Lab testing is essential before and during Zepbound therapy. A comprehensive thyroid panel should include TSH, free T4, free T3, and calcitonin. For patients with pre-existing thyroid conditions, additional markers like anti-TPO and anti-thyroglobulin antibodies may be warranted. Testing at mylabpanel.com provides accurate, CLIA-certified results with convenient at-home collection options.
Zepbound does not routinely alter thyroid hormone levels in humans, but caution is warranted due to the theoretical risk of C-cell stimulation. Routine monitoring with a thyroid panel is the standard of care for all patients starting this medication. For personalized insights, order a comprehensive thyroid panel from mylabpanel.com to establish baseline values and track changes over time.
Ready to take control of your thyroid health while on Zepbound? Order your thyroid panel today and receive professional interpretation of your results.
Ready to order your test?
Order online in 2 minutes and visit a local lab same day.
Find a Lab Near MeZepbound has a black box warning for thyroid C-cell tumors based on animal studies, but no conclusive evidence in humans. Patients with a personal or family history of medullary thyroid carcinoma should not use Zepbound.
Yes, a baseline thyroid panel including TSH, free T4, and calcitonin is recommended before starting Zepbound to assess any pre-existing abnormalities.
Monitoring every 3 months during the first year and annually thereafter is standard. More frequent testing is needed if you have thyroid disease or symptoms.
Affiliate disclosure: MyLabPanel may earn a commission when you book a test through links on this page, at no extra cost to you.